Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
Eylea, which is used to treat age-related macular degeneration, brought in roughly $9.4 billion in sales last year, down a ...
Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update)
Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, ...
Regeneron's Injunction on Eylea Biosimilar Holds Up on Appeal
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
pharmaphorum5y
FDA approves Regeneron's Eylea for diabetic retinopathy
Eylea is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. It is designed to block the growth of new blood vessels and decrease the ability of fluid to ...
Nasdaq1mon
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
EYLEA HD and EYLEA are administered by injection into the eye. You should not use EYLEA HD or EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of ...
Investopedia26d
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
agreed to review their AVTO6 treatment for eye disorders. The treatment could compete with Regeneron Pharmaceuticals’ (REGN) Eylea, which is widely used to treat diseases such as neovascular ...
Seeking Alpha26d
Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea
blockbuster eye disease therapy, Eylea. A biologic named AVT06, Teva (NYSE:TEVA), and Alvotech’s (NASDAQ:ALVO) biosimilar, is backed by positive data from a clinical trial for patients with ...